Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparing Medications for Adults With Type 2 Diabetes

Slide: 23 of 35

Details of Lipid Intermediate Outcomes: Comparisons of Two-Drug Combination Therapies

LIPIDS 
The addition of rosiglitazone to metformin increased LDL and HDL but also increased TG when compared to the combination of metformin and a sulfonylurea.
The addition of pioglitazone to metformin also increased HDL but decreased TG when compared to the combination of metformin and a sulfonylurea.

LDL
The combination of metformin and a sulfonylurea decreased LDL more than the combination of metformin and rosiglitazone (pooled between-group difference -13.5  mg/dL, 95 percent CI -17.9 mg/dL to -9.1 mg/dL), with moderate strength of evidence.

HDL
The combination of rosiglitazone or pioglitazone with metformin increased HDL compared to the combination of metformin and a sulfonylurea. The strength of evidence was graded as moderate for these comparisons. The combination of sulfonylurea plus pioglitazone was favored over the combination of metformin plus sulfonylurea. The strength of evidence was graded as low for this comparison.

TG
The combination of metformin and rosiglitazone had similar effects on TG compared to a combination of metformin and a sulfonylurea, with moderate strength of  evidence. The combination of metformin and pioglitazone decreased TG compared to the combination of metformin and a sulfonylurea by about 15 mg/dL, with  moderate strength of evidence.